インデックス付き
  • 学術雑誌データベース
  • Jゲートを開く
  • Genamics JournalSeek
  • ジャーナル目次
  • 中国国家知識基盤 (CNKI)
  • シマゴ
  • ウルリッヒの定期刊行物ディレクトリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • パブロン
  • ミアル
  • 大学補助金委員会
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • Google スカラー
このページをシェアする

概要

HBV Vaccination in the Patient with Chronic Renal Disease

Ennio Duranti1 and Diletta Duranti2*

Patients undergoing hemodialysis often present with a reduced response to anti-hepatitis B virus (anti-HBV) vaccination. The soluble form of CD40 (sCD40) is elevated in hemodialysis patients and this has been shown to correlate with lack of response to anti-HBV vaccination. Due to its high molecular weight, conventional dialyzers cannot clear sCD40. Dialysis membranes in polymethylmethacrylate (PMMA) can reduce the levels of sCD40. We have used PMMA membranes in patients who were non-responders to anti-HBV vaccination (anti-HB antibody level<10 UI/L after 2 vaccinations circles). Interestingly, we found that significantly more patients in the PMMA group were able to mount a response to vaccination, compared to the control group.